Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Prothena Corporation plc (PRTA : NSDQ)
 
 • Company Description   
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.

Number of Employees: 82

 
 • Price / Volume Information   
Yesterday's Closing Price: $26.30 Daily Weekly Monthly
20 Day Moving Average: 523,616 shares
Shares Outstanding: 46.81 (millions)
Market Capitalization: $1,231.00 (millions)
Beta: 1.37
52 Week High: $79.75
52 Week Low: $21.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.25% -20.58%
12 Week -21.89% -15.58%
Year To Date -46.76% -36.94%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS
-
DUBLIN,L2 D02 VK60
IRL
ph: 011-353-1236-2500
fax: 353-1902-3510
ellen.rose@prothena.com http://www.prothena.com
 
 • General Corporate Information   
Officers
Gene G. Kinney - Chief Executive Officer; President and Director
Lars G. Ekman - Chairman
Tran B. Nguyen - Chief Strategy Officer and Chief Financial Officer
Karin L. Walker - Chief Accounting Officer
Paula K. Cobb - Director

Peer Information
Prothena Corporation plc (CORR.)
Prothena Corporation plc (RSPI)
Prothena Corporation plc (CGXP)
Prothena Corporation plc (BGEN)
Prothena Corporation plc (GTBP)
Prothena Corporation plc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G72800108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 46.81
Most Recent Split Date: (:1)
Beta: 1.37
Market Capitalization: $1,231.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.53 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 21.56
PEG Ratio: -
Price Ratios
Price/Book: 2.63
Price/Cash Flow: 16.61
Price / Sales: 6.11
EPS Growth
vs. Year Ago Period: 14.29%
vs. Previous Quarter: -9.86%
Sales Growth
vs. Year Ago Period: 620.63%
vs. Previous Quarter: -1.62%
ROE
03/31/22 - 16.25
12/31/21 - 18.11
09/30/21 - 23.20
ROA
03/31/22 - 12.05
12/31/21 - 13.02
09/30/21 - 15.59
Current Ratio
03/31/22 - -
12/31/21 - 17.48
09/30/21 - 20.81
Quick Ratio
03/31/22 - -
12/31/21 - 17.48
09/30/21 - 20.81
Operating Margin
03/31/22 - 33.45
12/31/21 - 33.39
09/30/21 - 34.76
Net Margin
03/31/22 - 33.45
12/31/21 - 33.39
09/30/21 - 34.76
Pre-Tax Margin
03/31/22 - -
12/31/21 - 35.86
09/30/21 - 37.37
Book Value
03/31/22 - -
12/31/21 - 10.00
09/30/21 - 10.53
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©